NewsBenzingaCorcept Therapeutics annuncia i risultati della Parte A del suo studio di fase 2 BELLA su Lifyorli in combinazione con nab-paclitaxel e bevacizumab in pazienti con carcinoma ovarico; Lifyorli in combinazione con nab-paclitaxel e bevacizumab ha... Corcept Therapeutics annuncia i risultati della Parte A del suo studio di fase 2 BELLA su Lifyorli in combinazione con nab-paclitaxel e bevacizumab in pazienti con carcinoma ovarico; Lifyorli in combinazione con nab-paclitaxel e bevacizumab ha... Benzinga 2026.10.26 12:11 (GMT+0) Open on Benzinga Other news David Einhorn Bets on Aluminum in Q3: Here Are His New Stock Picks, Fund Changes Bernstein Maintains Market Perform on Tyson Foods, Raises Price Target to $72 Broadcom Stock Is Up Tuesday: AI Chip Diversification, Dec. 9 Earnings, Analyst Targets Bernstein Downgrades PepsiCo to Underperform, Lowers Price Target to $128 If You Invested $1000 In Humana Stock 20 Years Ago, You Would Have This Much Today What's Going On With Ouster Stock Tuesday?